Eleni Papachristoforou

ORCID: 0000-0003-1553-1405
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Diabetes and associated disorders
  • Alcohol Consumption and Health Effects
  • Drug Transport and Resistance Mechanisms
  • Immune cells in cancer
  • Liver physiology and pathology
  • Plant Molecular Biology Research
  • Phagocytosis and Immune Regulation
  • Chromosomal and Genetic Variations
  • Pancreatic function and diabetes
  • Genomics and Chromatin Dynamics
  • Pancreatic and Hepatic Oncology Research

University of Edinburgh
2021-2024

MRC Centre for Regenerative Medicine
2024

Centre for Inflammation Research
2021-2024

The Queen's Medical Research Institute
2021-2022

Complement receptor of immunoglobulin superfamily (CRIg) is expressed on liver macrophages and directly binds complement component C3b or Gram-positive bacteria to mediate phagocytosis. CRIg plays important roles in several immune-mediated diseases, but it not clear how its pathogen recognition phagocytic functions maintain homeostasis prevent disease. We previously associated cytolysin-positive Enterococcus faecalis with severity alcohol-related Here, we demonstrate that reduced tissues...

10.1038/s41467-021-27385-3 article EN cc-by Nature Communications 2021-12-09

Abstract Cellular identity requires the concerted action of multiple transcription factors (TFs) bound together to enhancers cell-type-specific genes. Despite TFs recognizing specific DNA motifs within accessible chromatin, this information is insufficient explain how select 1 . Here we compared four different TF combinations that induce cell states, analysing genome occupancy, chromatin accessibility, nucleosome positioning and 3D organization at resolution. We show motif recognition on...

10.1038/s41586-024-08333-9 article EN cc-by Nature 2024-12-18

Background: The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction–associated steatohepatitis (MASH)-related fibrosis. INT-767, potent FXR agonist, has shown promise in preclinical models. We aimed to define the mechanisms of INT-767 activity experimental MASH and dissect cellular molecular targets agonism human disease. Methods: Leptin-deficient ob / mice were fed MASH-inducing diet 15 weeks before study started. After baseline liver biopsy stratification,...

10.1097/hc9.0000000000000574 article EN cc-by-nc-nd Hepatology Communications 2024-11-25
Coming Soon ...